Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/05/033537
CTRI/2021/05/033537
Not yet recruiting
未知

Colchicine for treating SARS-CoV-2 infection in maintenance hemodialysis patients: a prospective, open label, randomized controlled trial - NI

CMC Fluid research Funding0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
CMC Fluid research Funding
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
CMC Fluid research Funding

Eligibility Criteria

Inclusion Criteria

  • •Patients with end stage kidney disease who are on maintenance hemodialysis in our institute, who develop SARS\-CoV\-2 infection and who do not meet exclusion criteria, after written informed consent.

Exclusion Criteria

  • •1\.Age \< 18 years
  • •2\.Not willing to enter the study
  • •3\.Known hypersensitivity to colchicine.
  • •4\.Inflammatory bowel disease, chronic diarrhea or malabsorption
  • •5\.Previous neuromuscular disease
  • •6\.Cirrhosis, active chronic hepatitis or severe hepatic disease defined by SGOT or SGPT levels three times above the normal upper limit
  • •7\.Treatment with immunosuppressive agents, corticosteroids or interleukine\-1 antagonists for 6 months before inclusion
  • •8\.Pregnant or breastfeeding females
  • •9\.Patient currently taking colchicine for indications other than SARS\-CoV\-2 infection prophylaxis
  • •10\.History of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Will colchicine be useful as an agent to prevent SARS-CoV-2 infection in kidney failure patients who are on maintenance hemodialysis?
CTRI/2021/05/033605CMC Fluid research Funding
Recruiting
Not Applicable
Treatment of Sars-CoV2 infections (Covid-19) with valsartan vs placebo, a three-armed randomized, partly blinded trialCovid-19
DRKS00021732Klinikum St. Georg gGmbH300
Not yet recruiting
Not Applicable
se of Hemopurifier Device For The Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
CTRI/2021/10/037591Aethlon Medical Inc
Active, not recruiting
Phase 1
COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)Men and women over 40 years of age, with a diagnosis of COVID-19 infection and at least one high risk criterion.Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-001689-12-ESMONTREAL HEART INSTITUTE1,000
Active, not recruiting
Phase 1
Hydroxychloroquine as a treatment for coronavirus disease COVID-19
EUCTR2020-000890-25-FRFondation Méditerranée Infection (FMI) - IHU Méditerranée Infection25